Vol. 4 No. 1 (2017): January-December 2017

Published: 2017-12-31

Editorial (on invitation only)

Exploring the Advancing Function of Health Technology Assessments

Aileen Murphy

1-2
- PDF
DOI: https://doi.org/10.33393/grhta.2017.367
When Simple Becomes Complicated: Why Excel Should Lose its Place at the Top Table

Gianluca Baio, Anna Heath

3-6
- PDF
DOI: https://doi.org/10.33393/grhta.2017.368
Value of health technologies, HTA and decisions Valore delle tecnologie sanitarie, HTA, decisioni

Carlo Lucioni, Claudio Jommi

41-43
- PDF
DOI: https://doi.org/10.33393/grhta.2017.374
Beyond cost-effectiveness, analysis. Value-based pricing and result-oriented financing as a pathway to sustainability for the national health system in Spain Más allá Del análisis Coste-Efectividad. Precios Basados en el Valor y Financiación Orientada a Resultados Como Vía de Sostenibilidad Para el SNS en España

Alvaro Hidalgo-Vega

60-64
- PDF
DOI: https://doi.org/10.33393/grhta.2017.377

Review

Economic Evaluation of Family-Based Therapies for Children and Adolescents: what do we know?

Sandy Tubeuf, Sophie Guthmuller

197-207
- PDF
DOI: https://doi.org/10.33393/grhta.2017.395

Point of View

Cardiovascular risk and increased plasma LDL cholesterol concentration: the role of the Regional Health Service Il rischio cardiovascolare e la concentrazione plasmatica del colesterolo LDL: il ruolo dei Servizi Sanitari Regionali

Patrizia Berto, Claudio Bilato, Enzo Bonora, Umberto De Conto, Maria Stella Graziani, Paolo Pauletto, Roberto Vettor, Alberto Zambon

44-46
- PDF
DOI: https://doi.org/10.33393/grhta.2017.375
The Feasibility Study: A Health Economics Perspective

Brenda Gannon

65-68
- PDF
DOI: https://doi.org/10.33393/grhta.2017.378
Outpatient management of oral anticoagulation treatment (OAT) in general practice: the “Medicina di Gruppo di Masate” experience La Gestione Ambulatoriale Della Terapia Anticoagulante Orale (TAO) Nelle Cure Primarie: L'esperienza Dell'Associazione “Medicina di Gruppo di Masate”

Fiorenzo Massimo Corti, Contardo Luigi Corbetta, Maria P. Consuelo Lampreda, Giovanni Gancitano, Matteo Dionisi

84-87
- PDF
DOI: https://doi.org/10.33393/grhta.2017.381
Place in therapy of olmesartan Qual è il Giusto Place in Therapy Dell'olmesartan?

Antonio Addis, Francesco Trotta

141-144
- PDF
DOI: https://doi.org/10.33393/grhta.2017.388

Original Research Articles

Evaluating national pricing policies of innovative anti-cancer drugs: correlation analysis between costs and survival in 15 European countries Valutazione Della Politica di Pricing Dei Farmaci Oncologici Innovativi: Correlazione Tra Costi e Sopravvivenza in 15 Paesi Europei

Daniele Mengato, Francesca Decannas

7-10
- PDF
DOI: https://doi.org/10.33393/grhta.2017.369
Economic evaluation of platelet-rich-plasma versus hyaluronic acid for the treatment of knee osteoarthritis. Scenarios to 1 and 5 years Valutazione Economica Sull'utilizzo Del Plasma Arricchito di Piastrine Vs Acido Ialuronico Per il Trattamento Dell'osteoartrosi al Ginocchio. Scenario a 1 Anno e a 5 Anni

Stefano Landi, Paolo Landa, Salvatore Russo

11-21
- PDF
DOI: https://doi.org/10.33393/grhta.2017.370
Cost analysis of residual viremia detected by two real-time PCR assays for response-guided (dual or triple) therapy of HCV genotype 1 infection Analisi Economica Associata all'utilizzo Di Due Test (Real-Time PCR-Based) per Valutare La Determinazione Dell'HCV-RNA Nei Pazienti HCV Genotipo 1 in Trattamento Con Duplice o Triplice Terapia

Alessio Aghemo, Giovanna Lunghi, Roberto Ravasio, Erminio Torresani, Matteo Dionisi, Davide Paolini, Massimo Colombo

22-27
- PDF
DOI: https://doi.org/10.33393/grhta.2017.371
The Burden of Healthcare Costs Associated with Prostate Cancer in Ireland

Richéal M. Burns, Jose Leal, Jane Wolstenholme, Ciaran O’Neill, Frank J. Sullivan, Frances J. Drummond, Linda Sharp

28-33
- PDF
DOI: https://doi.org/10.33393/grhta.2017.372
Rapid Reviews with Health-Technology Assessments in Reimbursement Systems – an Examination of Ireland as a Case Study

Aileen Murphy, Sandra Redmond

34-40
- PDF
DOI: https://doi.org/10.33393/grhta.2017.373
Intravitreal corticosteroids for the treatment of macular edema: review and assessment of quality of the evidence Corticosteroidi per via Intravitreale per il Trattamento Dell'edema Maculare: Revisione e Valutazione Della Qualità Dell'evidenza

Marco Marchetti, Luz Irene Urbina, Marco Oradei, Matteo Ruggeri, Pierluigi Navarra

47-59
- PDF
DOI: https://doi.org/10.33393/grhta.2017.376
Budget impact analysis of ticagrelor for preventive treatment of patients with acute coronary syndromes Analisi di Budget Impact di Ticagrelor nel Trattamento di Prevenzione in Pazienti con Sindrome Coronarica Acuta

Gian Piero Perna, Roberto Ravasio, Antonio Ricciardelli

69-76
- PDF
DOI: https://doi.org/10.33393/grhta.2017.379
The cost of Clostridium difficile infection (CDI) in hospital in Italy Il Costo Ospedaliero di Trattamento di un Episodio di Infezione da Clostridium Difficile in Italia

Nicola Petrosillo, Roberto Ravasio

77-83
- PDF
DOI: https://doi.org/10.33393/grhta.2017.380
Activity-based costing and budget analysis of vedolizumab versus conventional treatments in ulcerative colitis and Crohn's disease Analisi Organizzativa e di Budget Dell'introduzione di Vedolizumab Vs Terapie Tradizionali in Colite Ulcerosa e Morbo di Crohn

Matteo Ruggeri, Michele Basile, Alessandro Armuzzi, Americo Cicchetti

88-99
- PDF
DOI: https://doi.org/10.33393/grhta.2017.382
Mortality Cost of Duchenne Muscular Dystrophy

Erik Landfeldt, Michelle Eagle, Volker Straub, Hanns Lochmüller, Katharine Bushby, Peter Lindgren

100-103
- PDF
DOI: https://doi.org/10.33393/grhta.2017.383
Analysis of Productivity Costs in Cancer: A Systematic Review

Jordi Gol-Montserrat, María Luisa M. del Burgo, Luis Quecedo, Juan E. del Llano

104-113
- PDF
DOI: https://doi.org/10.33393/grhta.2017.384
Cost-Effectiveness of Azacitidine Compared with Low-Doses of Chemotherapy (LDC) in Myelodysplastic Syndrome (MDS)

Myrna Candelaria Hernández, Xavier López Karpovitch, Francisco Javier Mijangos, Efreen Montaño, Arely Lemus Carmona, Silvia Guzmán Vázquez, Herman Soto Molina

114-121
- PDF
DOI: https://doi.org/10.33393/grhta.2017.385
Budget impact analysis of empagliflozin in T2D patients with a previous cardiovascular disease Analisi di Impatto Sul Budget di Empagliflozin Nel Trattamento Dei Pazienti Con Diabete di tipo 2 e Malattia Cardiovascolare Accertata

Sergio Iannazzo, Aldo Pietro Maggioni, Edoardo Mannucci

122-132
- PDF
DOI: https://doi.org/10.33393/grhta.2017.386
Economic evaluation of lenalidomide (Revlimid®) for the treatment of mielodysplastic syndrome with 5q deletion at low/intermediate-1 risk Evaluación Económica de Lenalidomida (Revlimid®) Para el Tratamiento Del Síndrome Mielodisplásico Con Deleción 5q de Riesgo Bajo/Intermedio-1

Christian Ramos, Efreen Montaño, Alfonso Reyes-López, Fabiola Lemus, Maria Pacheco, Gabriela Hernandez, Arely Lemus

133-140
- PDF
DOI: https://doi.org/10.33393/grhta.2017.387
Economic evaluation of the organizational impact of adopting different in situ hybridization technologies to assess HER2 gene amplification in breast cancer Valutazione Economica Dell'impatto Organizzativo di Differenti Tecniche di Ibridazione in Situ per la Determinazione Dello Stato di HER2 nel Carcinoma Alla Mammella

Roberto Ravasio, Davide Paolini, Matteo Dionisi, Vincenzo Arena

145-148
- PDF
DOI: https://doi.org/10.33393/grhta.2017.426
Budget impact analysis in the maintenance raltegravir-containing regimen in virologically suppressed HIV infected patients Impatto Economico Dei Regimi Semplificati a Base di Raltegravir Nel Trattamento di Mantenimento Dei Pazienti HIV-1 Infetti in Soppressione Virologica

Roberto Ravasio, Mauro Maresca, Barbara Busà, Benedetto Maurizio Celesia

149-154
- PDF
DOI: https://doi.org/10.33393/grhta.2017.390
Including Health Economic Analysis in Pilot Studies: Lessons Learned from a Cost-Utility Analysis within the PROSPECTIV Pilot Study

Richéal M. Burns, Jane Wolstenholme, Bethany Shinkins, Emma Frith, Lauren Matheson, Peter W. Rose, Eila Watson

165-174
- PDF
DOI: https://doi.org/10.33393/grhta.2017.392
Economic impact of biosimilar drugs in Italy: past, present and future of infliximab and etanercept Impatto Economico Dei Biosimilari in Italia: Passato, Presente e Futuro di Infliximab ed Etanercept

Andrea Marcellusi, Luca Bianchi, Antonio Gasbarrini, Guido Valesini, Francesco Saverio Mennini

175-186
- PDF
DOI: https://doi.org/10.33393/grhta.2017.393
Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations Il Costo Degli Eventi Avversi Associati ad Afatinib, Erlotinib e Gefitinib Nel Trattamento del Tumore del Polmone non a Piccole Cellule con Mutazione EGFR

Adolfo Favaretto, Francesco Grossi, Alessandro Morabito, Roberto Ravasio

187-196
- PDF
DOI: https://doi.org/10.33393/grhta.2017.394
Drug utilization of biological drugs in the treatment of chronic Immune-Mediated Inflammatory Diseases (IMIDs): an observational study on Italian patients Analisi di Farmacoutilizzazione dei Trattamenti Biologici Nelle Malattie Infiammatorie Immunomediate Croniche: I Risultati di Uno Studio Osservazionale Retrospettivo Condotto in un Centro Ospedaliero del Centro Italia

Paolo Faccendini, Enrica Cantillo, Caterina Fanizza, Maria Grazia Celeste

208-215
- PDF
DOI: https://doi.org/10.33393/grhta.2017.396
A Cost Comparison of Biologic Treatment Regimens for Metastatic Colorectal Cancer in Italy

Sergio Iannazzo, Chiara Distante, Stefania Lopatriello, Roberto Bordonaro

221-226
- PDF
DOI: https://doi.org/10.33393/grhta.2017.398
Economic evaluation of therapeutic sequences in the treatment of patients with chronic lymphocytic leukemia and coexisting conditions Una Valutazione Economica Delle Sequenze Terapeutiche nel Trattamento di Prima Linea Della Leucemia Linfatica Cronica in Pazienti Unfit non Pretrattati

Antonio Cuneo, Roberto Ravasio, Nicola Amedeo Mazzanti

227-234
- PDF
DOI: https://doi.org/10.33393/grhta.2017.399
The cost of antibiotic therapy and antibiotic resistance for complicated intra-abdominal infections (cIAIs) and complicated urinary tract infections (cUTIs) in Italy Il Costo Della Terapia Antibiotica e Dell'antibiotico-Resistenza Nelle Infezioni Intraddominali e Urinarie Complicate: l'esperienza di un Grande Presidio Ospedaliero Campano

Paola Saturnino, Maria Pia Mannelli, Roberto Ravasio

235-242
- PDF
DOI: https://doi.org/10.33393/grhta.2017.400
Current Management of Severe Refractory Asthma in Italy: Analysis of Real-World Data

Antonella Pedrini, Elisa Rossi, Silvia Calabria, Letizia Dondi, Nello Martini

216-220
- PDF
DOI: https://doi.org/10.33393/grhta.2017.397

Short Communication

Cost Advantage of Fluocinolone Acetonide Implant (ILUVIEN®) versus Ranibizumab in the Treatment of Chronic Diabetic Macular Oedema

Fahd Quhill, Annette Beiderbeck

155-164
- PDF
DOI: https://doi.org/10.33393/grhta.2017.391

Vol. 4 No. 1 (2017): January-December 2017

Editorial (on invitation only)

Exploring the Advancing Function of Health Technology Assessments

When Simple Becomes Complicated: Why Excel Should Lose its Place at the Top Table

Value of health technologies, HTA and decisions Valore delle tecnologie sanitarie, HTA, decisioni

Review

Economic Evaluation of Family-Based Therapies for Children and Adolescents: what do we know?

Point of View

Cardiovascular risk and increased plasma LDL cholesterol concentration: the role of the Regional Health Service Il rischio cardiovascolare e la concentrazione plasmatica del colesterolo LDL: il ruolo dei Servizi Sanitari Regionali

The Feasibility Study: A Health Economics Perspective

Outpatient management of oral anticoagulation treatment (OAT) in general practice: the “Medicina di Gruppo di Masate” experience La Gestione Ambulatoriale Della Terapia Anticoagulante Orale (TAO) Nelle Cure Primarie: L'esperienza Dell'Associazione “Medicina di Gruppo di Masate”

Place in therapy of olmesartan Qual è il Giusto Place in Therapy Dell'olmesartan?

Original Research Articles

Evaluating national pricing policies of innovative anti-cancer drugs: correlation analysis between costs and survival in 15 European countries Valutazione Della Politica di Pricing Dei Farmaci Oncologici Innovativi: Correlazione Tra Costi e Sopravvivenza in 15 Paesi Europei

The Burden of Healthcare Costs Associated with Prostate Cancer in Ireland

Rapid Reviews with Health-Technology Assessments in Reimbursement Systems – an Examination of Ireland as a Case Study

Intravitreal corticosteroids for the treatment of macular edema: review and assessment of quality of the evidence Corticosteroidi per via Intravitreale per il Trattamento Dell'edema Maculare: Revisione e Valutazione Della Qualità Dell'evidenza

Budget impact analysis of ticagrelor for preventive treatment of patients with acute coronary syndromes Analisi di Budget Impact di Ticagrelor nel Trattamento di Prevenzione in Pazienti con Sindrome Coronarica Acuta

The cost of Clostridium difficile infection (CDI) in hospital in Italy Il Costo Ospedaliero di Trattamento di un Episodio di Infezione da Clostridium Difficile in Italia

Activity-based costing and budget analysis of vedolizumab versus conventional treatments in ulcerative colitis and Crohn's disease Analisi Organizzativa e di Budget Dell'introduzione di Vedolizumab Vs Terapie Tradizionali in Colite Ulcerosa e Morbo di Crohn

Mortality Cost of Duchenne Muscular Dystrophy

Analysis of Productivity Costs in Cancer: A Systematic Review

Cost-Effectiveness of Azacitidine Compared with Low-Doses of Chemotherapy (LDC) in Myelodysplastic Syndrome (MDS)

Budget impact analysis of empagliflozin in T2D patients with a previous cardiovascular disease Analisi di Impatto Sul Budget di Empagliflozin Nel Trattamento Dei Pazienti Con Diabete di tipo 2 e Malattia Cardiovascolare Accertata

Economic evaluation of lenalidomide (Revlimid®) for the treatment of mielodysplastic syndrome with 5q deletion at low/intermediate-1 risk Evaluación Económica de Lenalidomida (Revlimid®) Para el Tratamiento Del Síndrome Mielodisplásico Con Deleción 5q de Riesgo Bajo/Intermedio-1

Budget impact analysis in the maintenance raltegravir-containing regimen in virologically suppressed HIV infected patients Impatto Economico Dei Regimi Semplificati a Base di Raltegravir Nel Trattamento di Mantenimento Dei Pazienti HIV-1 Infetti in Soppressione Virologica

Including Health Economic Analysis in Pilot Studies: Lessons Learned from a Cost-Utility Analysis within the PROSPECTIV Pilot Study

Economic impact of biosimilar drugs in Italy: past, present and future of infliximab and etanercept Impatto Economico Dei Biosimilari in Italia: Passato, Presente e Futuro di Infliximab ed Etanercept

A Cost Comparison of Biologic Treatment Regimens for Metastatic Colorectal Cancer in Italy

Economic evaluation of therapeutic sequences in the treatment of patients with chronic lymphocytic leukemia and coexisting conditions Una Valutazione Economica Delle Sequenze Terapeutiche nel Trattamento di Prima Linea Della Leucemia Linfatica Cronica in Pazienti Unfit non Pretrattati

Current Management of Severe Refractory Asthma in Italy: Analysis of Real-World Data

Short Communication

Cost Advantage of Fluocinolone Acetonide Implant (ILUVIEN®) versus Ranibizumab in the Treatment of Chronic Diabetic Macular Oedema

Browse

banners150

Vol. 4 No. 1 (2017): January-December 2017

Editorial (on invitation only)

Review

Point of View

Original Research Articles

Short Communication

Sign up

Browse

banners150